Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Kraton provides update on COVID-19 impact » 06:12
03/30/20
03/30
06:12
03/30/20
06:12
KRA

Kraton

$6.68 /

-0.315 (-4.51%)

Kraton provided a status…

Kraton provided a status update related to the COVID-19 pandemic impact on the company. Kraton continues to monitor the progression of the COVID-19 pandemic on a daily, if not hourly basis. While essential plant and laboratory personnel remain on-site, many employees are working remotely. The company continues to follow the orders and guidance of Federal, regional and local governmental agencies, as it maintains protocols in an effort to mitigate the spread of the virus and protect the health of employees, customers and suppliers as well as the communities. The Ccmpany continues to strengthen its balance sheet, most recently through the March 6 sale of its Cariflex business for $530M and the subsequent reduction in amounts outstanding under its senior secured term loan facility. For Q1, the company expects to report Adjusted EBITDA exceeding the current consensus estimate of approximately $46M. The company expects to release full results for Q1 after market close on April 29 and host a call to discuss Q1 results the morning of April 30. "To date, COVID-19 has had a limited impact on our business and results of operations. Our plants have continued to operate at normal capacities, and our supply chain remains intact, with adequate availability of key raw materials. Importantly, under the U.S. Department of Homeland Security guidance issued on March 19, as well as many related regional and local governmental orders, chemical manufacturing sites are considered essential critical infrastructure, and as such, are not currently subject to closure in the locations where we operate. While the European Union issues critical infrastructure orders on a country-by-country basis, thus far they have taken a similar approach to the U.S. Department of Homeland Security guidance," said Kevin Fogarty, Kraton's CEO. "Although there has been some disruption in global logistics channels, we have not experienced significant delays in fulfillment of customer orders. While the future remains uncertain, we believe Kraton's geographic and end market diversification remains a strength, as we serve many customers, including those in medical, adhesive and food packaging industries, whose products remain vital in the current environment," added Fogarty.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Kraton partocipates in a conference call with Loop Capital » 04:55
03/24/20
03/24
04:55
03/24/20
04:55
KRA

Kraton

$4.70 /

-1.31 (-21.80%)

Loop Capital hosts a…

Loop Capital hosts a conference call with CEO Fogarty & CFO Atanasov on March 24.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Kraton partocipates in a conference call with Loop Capital » 08:40
03/23/20
03/23
08:40
03/23/20
08:40
KRA

Kraton

$6.01 /

+0.36 (+6.37%)

Loop Capital hosts a…

Loop Capital hosts a conference call with CEO Fogarty & CFO Atanasov on March 24.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Recommendations
Kraton price target lowered to $14 from $24 at SunTrust » 09:28
02/28/20
02/28
09:28
02/28/20
09:28
KRA

Kraton

$10.38 /

-2.06 (-16.56%)

SunTrust analyst James…

SunTrust analyst James Sheehan lowered the firm's price target on Kraton to $14 from $24 but keeps a Buy rating on the shares. The analyst cites the company's 9% EBITDA miss reported in Q4 along with an expected 21% decline in its guided EBITDA for 2020 amid continued margin pressure in the CST and TOR product chains in addition to the coronavirus impact concerns. Sheehan believes however that after a 41% year-to-date decline, there is support at Kraton's expected 2020 EBITDA multiple of 6.3-times.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Kraton price target lowered to $30 from $38 at Loop Capital » 09:17
02/28/20
02/28
09:17
02/28/20
09:17
KRA

Kraton

$10.38 /

-2.06 (-16.56%)

Loop Capital analyst…

Loop Capital analyst Chris Kapsch lowered the firm's price target on Kraton to $30 from $38 but keeps a Buy rating on the shares. The analyst notes that the company had a "challenging" 2019 due to adverse macro and key end-market considerations, with added uncertainty regarding its near-term earnings trajectory coming from the impact of coronavirus. Kapsch adds however that it is "difficult" to imagine that investors would not profit by buying Kraton shares at the current beaten down valuations.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Kraton sees FY20 adjusted EBITDA $200M-$220M  16:54
02/26/20
02/26
16:54
02/26/20
16:54
KRA

Kraton

$12.44 /

-0.77 (-5.83%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Kraton reports Q4 adjusted EPS (6c), consensus 4c » 16:53
02/26/20
02/26
16:53
02/26/20
16:53
KRA

Kraton

$12.44 /

-0.77 (-5.83%)

Reports Q4 revenue…

Reports Q4 revenue $408.52M, consensus $386.52M.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Kraton price target lowered to $24 from $31 at SunTrust » 08:21
02/25/20
02/25
08:21
02/25/20
08:21
KRA

Kraton

$14.86 /

-1.12 (-7.01%)

SunTrust analyst James…

SunTrust analyst James Sheehan cut his price target on Kraton to $24 to reflect the expected lower Polymer and Chemical volumes in Q1 due to coronavirus outbreak as well as the lower Chemical margins due to reduced fixed cost absorption and higher crude tall oil input costs. The analyst still keeps his Buy rating on Kraton shares longer term given its "attractive" valuation at 5.1-times his expected FY20 EBITDA.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a quarter ago
On The Fly
Two double upgrades of chipmakers top today's list of notable Wall Street calls » 11:06
12/09/19
12/09
11:06
12/09/19
11:06
SOX

PHLX Semiconductor Sector Index

$0.00 /

+ (+0.00%)

, QRVO

Qorvo

$109.99 /

+3.31 (+3.10%)

, SWKS

Skyworks

$103.95 /

+2.55 (+2.51%)

, KRA

Kraton

$23.93 /

+0.89 (+3.86%)

, DOW

Dow Inc.

$53.32 /

+0.07 (+0.13%)

, MMM

3M

$170.52 /

-0.97 (-0.57%)

, FTV

Fortive

$74.57 /

+1.71 (+2.35%)

, M

Macy's

$15.36 /

+0.21 (+1.39%)

, CVX

Chevron

$117.63 /

-0.35 (-0.30%)

Check out today's top…

Open Full Text

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Fly Intel: Top five analyst upgrades » 10:20
12/09/19
12/09
10:20
12/09/19
10:20
QRVO

Qorvo

$109.72 /

+3.04 (+2.85%)

, SWKS

Skyworks

$104.55 /

+3.15 (+3.11%)

, FATE

Fate Therapeutics

$19.69 /

+6.05 (+44.35%)

, WING

Wingstop

$84.26 /

+4.04 (+5.04%)

, HUN

Huntsman

$23.31 /

+0.48 (+2.10%)

, FTV

Fortive

$74.68 /

+1.82 (+2.50%)

, DOW

Dow Inc.

$53.29 /

+0.04 (+0.08%)

, KRA

Kraton

$23.96 /

+0.92 (+3.99%)

Catch up on today's…

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Qorvo (QRVO) and Skyworks (SWKS) double upgraded to Buy from Underperform at BofA/Merrill. 2. Fate Therapeutics (FATE) upgraded to Outperform from Market Perform at Wells Fargo with analyst Jim Birchenough citing this weekend's update for the company's iPSC-derived NK-cell therapeutics pipeline, initial data for iPSC NKcell therapies FT500 and FT516, and updated comments on CD19 CAR-NK therapeutic FT596. 3. Wingstop (WING) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Katherine Fogertey saying while the shares are up over 30% over the past year, they have lagged the S&P 500 by over 30% since August 22 and now trade at a discount to peers. 4. Huntsman (HUN) and Fortive (FTV) upgraded to Buy from Neutral at Citi. 5. Dow Inc. (DOW) and Kraton (KRA) upgraded to Buy from Hold at SunTrust. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.